Conference Reports for NATAP

Back

XVII International HIV Drug Resistance Workshop June 10-14, 2008, Sitges, Spain     Report on the XV11 International Drug Resistance Workshop, June 10-14, 2008, Sitges, Spain - Written by Mark A Wainberg - (06/24/08)   Etravirine Resistance   Tibotec Etravirine Weighted Genotype Score to Predict Response - (06/20/08)   Tibotec Analysis: Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR) - (06/20/08)   Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/19/08)   Virco Etravirine Clinical Cutoffs - (06/18/08)   Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week 24 results of the DUET-1 and DUET-2 trials - (06/17/08)   Biological and Clinical Cutoff Analyses for Etravirine in the PhenoSense HIV Assay - (06/17/08)   Monogram Devises Weighted Genotypic Score to Predict Etravirine Response - Written by Mark Mascolini - (06/17/08)   Low-End Clinical Cutoff Proposed for Etravirine - Written by Mark Mascolini - (06/17/08)   Raltegravir Resistance   Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens - (06/24/08)   HIV DNA Viral Load Evolution under a Raltegravir-based Therapy: modest decline, authors say "these findings suggest raltegravir may be protective from infection to newly CD4 cells generated during treatment" - (06/19/08)   Merck's Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from P005 a Phase 2 Study in Treatment Experienced Patients - (06/18/08)   Mechanism by which the HIV Integrase Active Site Mutation N155H Confers Resistance to Raltegravir - (06/18/08)   Impact of Raltegravir on HIV DNA--and Fitness of Raltegravir-Resistant Virus - Written by Mark Mascolini - (06/16/08)   Early Clues From Raltegravir Failure in Clinical Practice; Diverse Patterns of Resistance Mutations - Written by Mark Mascolini - (06/16/08)   Novel Integrase Mutation Boosts Resistance to Elvitegravir and Raltegravir - Written by Mark Mascolini - (06/11/08)   Mutually Exclusive Resistance Paths Seen With Raltegravir Failure - Written by Mark Mascolini - (06/11/08)   Q148 Mutations Emerge as Primary Raltegravir Resistance Pathway - Written by Mark Mascolini - (06/11/08)   Routes to Cross-Resistance With Raltegravir and Elvitegravir - Written by Mark Mascolini - (06/11/08)   Resistance Mutations in HIV-1 Integrase Selected with Raltegravir or Elvitegravir Confer Reduced Susceptibility to a Diverse Panel of Integrase Inhibitors - (06/19/08)   Monogram HIV-1 Genotype Algorithms for Prediction of Etravirine Susceptibility: Novel Mutations and Weighting Factors Identified Through Correlations to Phenotype - (06/18/08)   Integrase Inhibitor Resistance (elvitegravir/raltegravir) Involves Complex Interactions Among Primary and Secondary Resistance Mutations: A Novel Mutation L68V/I Associates with E92Q and Increases Resistance - (06/19/08)   Virologic and Immunologic Outcomes in a Cohort of Subjects Failing Integrase Inhibitors - (06/20/08)   Virological Response and Resistance in Multi-Experienced Patients Treated with Raltegravir - (06/20/08)   Monogram Analysis: Loss of Raltegravir Susceptibility in Treated Patients is Conferred by Multiple Non-overlapping Genetic Pathways - (06/20/08)   Low frequency K103N mutations are strongly associated with inadequate virologic responses to NNRTI-based therapy. sdNVP & K103N - (06/26/08)   Identifying Low-Level CXCR4 Virus with Roche 454 Life Sciences Sensitive Assay - (06/25/08)   Comparable in-vitro susceptibility and virological outcome to darunavir in patients infected with subtype B and non-subtype B HIV isolates participating in the ARTEMIS Phase III trial - (06/25/08)   Detection of Low Abundance Drug Resistant HIV Variants in Treatment Experienced Subjects by Ultra Deep Sequencing (454 Life Sciences/Roche Test) - (06/25/08)   NNRTI Resistance in Naives 16%. Changes in Regional Prevalence, Clade and Epidemiology of HIV-1 Drug Resistance Mutations and Clade among Antiviral Therapy-Naive Patients in the United States (US) from 2000 to 2007 - (06/25/08)   HIV-1 resistance in Mozambican infants following prophylaxis with single-dose nevirapine (sdNVP) - (06/24/08)   Antiretroviral Intensification Does Not Reduce HIV-1 Viremia in Patients Suppressed on Standard Combination Therapy - (06/24/08)   No effect of subtype on susceptibility and virologic response to TPV/r for treatment experienced patients - (06/24/08)   Mutations 24I, 50L/V, 54L, and 76V, selected by other protease inhibitors, predict durable response to tipranavir in treatment experienced patients when two or more are present - (06/24/08)   Dynamics of emergence of CXCR4-using HIV in clinical samples as detected by Trofile and MT-2 assays - (06/20/08)   Technical Validation of an Enhanced Sensitivity Trofile HIV Co-receptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5 - (06/20/08)   Slightly Revised Darunavir Resistance Profile from Tibotec - (06/20/08)   Minority quasispecies of drug-resistant HIV-1 leading to early therapy failure in treatment-naive and adherent patients - (06/20/08)   Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/16/08)   Low-Level Pretreatment NNRTI Mutation May Imperil Virologic Response - Written by Mark Mascolini - (06/16/08)   Gene-Based Tools Getting Better at Predicting Coreceptor Use - Written by Mark Mascolini - (06/16/08)   Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America: 2000-2005 - (06/16/08)   HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457) (06/16/08)   Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG5211 Results. Using Enhanced Tropism Assay Improves Outcomes. (06/16/08)   Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/13/08)   Hexadecyloxypropyltenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favorable preclinical profile - (06/13/08)   Hexadecyloxypropyl Tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)   Hexadecyloxpropyl Tenofovir (CMX157) Has Enhanced Potency In Vitro Against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)   New Trofile Assay Would Have Improved Vicriviroc Response in ACTG 5211 - Written by Mark Mascolini - (06/13/08)   Cumulative Resistance Catalog Gives Clearer Picture of Salvage Picks - Written by Mark Mascolini - (06/13/08)   Supersensitive Genotyping Spots More Mutations in Lopinavir Monotherapy Trial - Written by Mark Mascolini - (06/13/08)   Intensifying Standard Regimens Does Not Lower Residual Plasma HIV RNA - Written by Mark Mascolini - (06/11/08)   Resistance Mutation Rate Rising in Treatment-Naive US Trial Enrollees - Written by Mark Mascolini - (06/11/08)   Resistance Risk Higher in Injecting Drug Users, Regardless of Adherence - Written by Mark Mascolini - (06/11/08)   Multiclass Resistance Rate--But Not All-Class Resistance--Falls in US and Canada - Written by Mark Mascolini - (06/11/08)   Five Mutations Tied to Better Tipranavir Response at 48 Weeks - Written by Mark Mascolini - (06/11/08)   NNRTI Mutation Rates With Failing EFV vs NVP in EuroSIDA - Written by Mark Mascolini - (06/11/08)   In Vitro Cross-Resistance Profile for a Next-Generation NNRT I: IDX899 (06/11/08)   Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naive HIV-1-Infected Subjects (06/11/08)   In Vitro Cross-Resistance Profile, Antiviral Activity, Safety and Pharmacokinetics in HIV-1 Infected Subjects of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance (06/11/08)